Evidence map›Paper›PMID 35072512›Full record

ArticleAntimicrobial agents and chemotherapy2022

Experimental Confirmation that an Uncommon

Pilar Domenech, Esma Mouhoub, Michael B Reed

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Pilar DomenechInfectious Diseases and Immunity in Global Health Program of The Research Institute of the McGill Universitygrid.14709.3b Health Centre, McGill University, Montreal, Quebec, Canada.
Esma MouhoubInfectious Diseases and Immunity in Global Health Program of The Research Institute of the McGill Universitygrid.14709.3b Health Centre, McGill University, Montreal, Quebec, Canada.
Michael B ReedInfectious Diseases and Immunity in Global Health Program of The Research Institute of the McGill Universitygrid.14709.3b Health Centre, McGill University, Montreal, Quebec, Canada.ORCID 0000-0002-1312-1480

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effective treatment of patients diagnosed with drug-resistant tuberculosis is highly dependent on the ability to rapidly and accurately determine the antibiotic susceptibility profile of the Mycobacterium tuberculosis isolate(s) involved. Thus, as more clinical microbiology laboratories advance toward the use of DNA sequence-based diagnostics, it is imperative that their predictive functions extend beyond the well-known resistance mutations in order to also encompass as many of the lower-frequency mutations as possible. However, in most cases, fundamental experimental proof that links these uncommon mutations with phenotypic resistance is lacking. One such example is the g878a polymorphism within the

Indexed as

Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsHumansMicrobial Sensitivity TestsMutationRNA, Ribosomal, 16SStreptomycinAntitubercular AgentsRNA, Ribosomal, 16SStreptomycinantibiotic resistanceMycobacterium tuberculosisrecombineeringstreptomycin

Identifiers

PMID35072512
PMCPMC8923206

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.